用于2型糖尿病患者的药物：超越降低糖化血红蛋白
Pharmacological Agents Utilized in Patients With Type-2 Diabetes: Beyond Lowering A1c.
作者信息
Chung Joanna W, Hartzler Melody L, Smith Ashley, Hatton Jessica, Kelley Kristi
出版信息
P T. 2018 Apr;43(4):214-227.
Abstract
Staying up to date with evolving pharmacotherapies is important to providing optimal therapies to patients. The authors present available evidence to support the role of novel and existing agents in treating type-2 diabetes.
摘要
紧跟不断发展的药物治疗方法对于为患者提供最佳治疗至关重要。作者提供了现有证据来支持新型药物和现有药物在治疗2型糖尿病中的作用。
相似文献
1
Pharmacological Agents Utilized in Patients With Type-2 Diabetes: Beyond Lowering A1c.用于2型糖尿病患者的药物：超越降低糖化血红蛋白
P T. 2018 Apr;43(4):214-227.
2
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.用于治疗肾移植受者中已存在的和新发糖尿病的降糖药物。
Cochrane Database Syst Rev. 2017 Feb 27;2(2):CD009966. doi: 10.1002/14651858.CD009966.pub2.
3
Network meta-analysis of glucose-lowering drug treatment regimens with the potential risk of hypoglycemia in patients with type 2 diabetes mellitus in terms of glycemic control and severe hypoglycemia.2型糖尿病患者降糖药物治疗方案低血糖潜在风险在血糖控制和严重低血糖方面的网状Meta分析
J Investig Med. 2023 Apr;71(4):400-410. doi: 10.1177/10815589221149188. Epub 2023 Jan 25.
4
Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control.对于已经接受胰岛素治疗但血糖控制不佳的2型糖尿病患者，胰岛素单药治疗与在胰岛素基础上加用口服降糖药的比较。
Cochrane Database Syst Rev. 2016 Sep 18;9(9):CD006992. doi: 10.1002/14651858.CD006992.pub2.
5
Managing type 2 diabetes: going beyond glycemic control.管理2型糖尿病：超越血糖控制
J Manag Care Pharm. 2008 Jun;14(5 Suppl B):s2-19.
6
Relationship of glycemic control to total diabetes-related costs for managed care health plan members with type 2 diabetes.2型糖尿病管理式医疗保健计划成员的血糖控制与糖尿病相关总费用的关系。
J Manag Care Pharm. 2005 Sep;11(7):559-64. doi: 10.18553/jmcp.2005.11.7.559.
7
Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus.1型或2型糖尿病患者血糖控制与糖尿病相关住院费用之间的关系。
J Manag Care Pharm. 2010 May;16(4):264-75. doi: 10.18553/jmcp.2010.16.4.264.
9
Impact of rosiglitazone therapy on the lipid profile, glycemic control, and medication costs among type 2 diabetes patients.罗格列酮治疗对 2 型糖尿病患者的血脂谱、血糖控制和药物费用的影响。
Curr Med Res Opin. 2011 Aug;27(8):1623-33. doi: 10.1185/03007995.2011.595001. Epub 2011 Jun 22.
10
Insulin for the treatment of women with gestational diabetes.用于治疗妊娠期糖尿病女性的胰岛素。
Cochrane Database Syst Rev. 2017 Nov 5;11(11):CD012037. doi: 10.1002/14651858.CD012037.pub2.
引用本文的文献
1
Trends in U.S. Insulin Use and Glucose Monitoring for People with Diabetes: 2009-2018.美国糖尿病患者胰岛素使用和血糖监测趋势：2009-2018 年。
J Diabetes Sci Technol. 2022 Nov;16(6):1428-1435. doi: 10.1177/19322968211028268. Epub 2021 Jul 5.
2
The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development.过氧化物酶体增殖物激活受体配体在临床药物研发中的机遇与挑战。
Int J Mol Sci. 2018 Jul 27;19(8):2189. doi: 10.3390/ijms19082189.
本文引用的文献
1
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.美国临床内分泌医师协会和美国内分泌学会关于2型糖尿病综合管理算法的共识声明 - 2018执行摘要
Endocr Pract. 2018 Jan;24(1):91-120. doi: 10.4158/CS-2017-0153. Epub 2018 Jan 17.
2
Introduction: .引言：.
Diabetes Care. 2018 Jan;41(Suppl 1):S1-S2. doi: 10.2337/dc18-Sint01.
3
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.每周一次艾塞那肽对2型糖尿病患者心血管结局的影响。
N Engl J Med. 2017 Sep 28;377(13):1228-1239. doi: 10.1056/NEJMoa1612917. Epub 2017 Sep 14.
4
Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm.是时候改变2型糖尿病的治疗模式了吗？答案是肯定的！胰高血糖素样肽-1受体激动剂（GLP-1 RAs）应在2型糖尿病治疗方案中取代二甲双胍。
Diabetes Care. 2017 Aug;40(8):1121-1127. doi: 10.2337/dc16-2368.
5
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.卡格列净与 2 型糖尿病的心血管和肾脏事件。
N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12.
6
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.德谷胰岛素与甘精胰岛素治疗2型糖尿病的疗效和安全性比较
N Engl J Med. 2017 Aug 24;377(8):723-732. doi: 10.1056/NEJMoa1615692. Epub 2017 Jun 12.
7
Association of glucagon-like peptide-1 receptor agonist use and rates of acute myocardial infarction, stroke and overall mortality in patients with type 2 diabetes mellitus in a large integrated health system.在一个大型综合医疗体系中，2 型糖尿病患者使用胰高血糖素样肽-1 受体激动剂与急性心肌梗死、中风和总死亡率的相关性。
Diabetes Obes Metab. 2017 Nov;19(11):1555-1561. doi: 10.1111/dom.12969. Epub 2017 Jul 5.
8
Managing glycaemia in older people with type 2 diabetes: A retrospective, primary care-based cohort study, with economic assessment of patient outcomes.老年2型糖尿病患者的血糖管理：一项基于初级保健的回顾性队列研究，并对患者结局进行经济评估。
Diabetes Obes Metab. 2017 May;19(5):644-653. doi: 10.1111/dom.12867. Epub 2017 Feb 23.
9
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial.利西拉来，一种基础胰岛素联合二甲双胍血糖控制不佳的 2 型糖尿病患者的可滴定固定比例复方制剂：LixiLan-L 随机试验的疗效和安全性。
Diabetes Care. 2016 Nov;39(11):1972-1980. doi: 10.2337/dc16-1495. Epub 2016 Sep 20.
10
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.司美格鲁肽与 2 型糖尿病患者的心血管结局
N Engl J Med. 2016 Nov 10;375(19):1834-1844. doi: 10.1056/NEJMoa1607141. Epub 2016 Sep 15.
Zotero 插件